Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
microRNA 6510 (miR-6510)
- Target
- miR-6510
- Molecular classification
- microRNA, Non-coding RNA, Epigenetic regulator, Other
01
Overview
microRNA 6510 (miR-6510, hsa-miR-6510) is a human microRNA—a short, non-coding RNA involved in post-transcriptional regulation of gene expression. It has been identified as significantly downregulated in head and neck squamous cell carcinoma, where it functions as a tumor suppressor. Upregulation or restoration of miR-6510-3p leads to cell cycle arrest at G2/M, induction of apoptosis, decreased cell proliferation, suppressed migration, reduced cancer stem cell marker expression (CD133, CD44), and heightened sensitivity to ionizing radiation. These properties make miR-6510-3p a potential therapeutic target and biomarker for HNSCC, though delivery and off-target effects remain technical challenges[1][2].
- Other names
- MIR6510mir-6510microRNA mir-6510hsa-miR-6510hsa-mir-6510
02
Mechanism of action
Gene silencing via RNA interference (downregulation of specific mRNA targets); Induction of cell cycle arrest and apoptosis as a result of gene regulation
03
Biological functions
Post-transcriptional regulation of gene expressionCell cycle control (G2/M arrest)Induction of apoptosis (cell death)Suppression of cell proliferation and migrationSuppression of stemness properties (reducing cancer stem cell phenotype)Increased sensitivity to ionizing radiation in cancer cells
04
Disease associations
Cancer (especially head and neck squamous cell carcinoma)Tumor suppressor activity in HNSCCAnti-cancer drug resistance (targets genes relevant for drug resistance)
05
Safety considerations
Challenges exist for delivery and tissue-specific modulation of microRNA therapeutics.Off-target effects and immune responses associated with RNA-based therapies remain theoretical concerns.No specific safety concerns for endogenous miR-6510; safety unknown for therapeutic manipulation.
06
Interacting drugs
No direct drugs currently interact with miR-6510, but targets of microRNA mimics/inhibitors or future RNA-based therapeutics may be relevant.
1 more in the full profile.
07
Biomarkers
Downregulation of miR-6510-3p in tumor tissue predicts poor recovery and survival in HNSCC patientsmiR-6510-3p levels potentially used to stratify patients or monitor therapeutic response
Beyond the preview
Go deeper on microRNA 6510 (miR-6510).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on microRNA 6510 (miR-6510).